IRCT201202279155N1已完成2 期
Evaluation of alendronate in prevention of steroid- induced osteopenia in childhood ALL and NH
Vice chancellor for research,Arak University of Medical Sciences0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- All
入选标准
- •inclusion criteria: children with ALL or NHL; informed consent form
- •exclusion criteria: Patient or parents desire to leave the study; Non-compliance with treatment regimen
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Efficacy of Alendronate for the Prevention of Bone Loss in Calcar Region Following Total Hip Arthroplasty.Osteoarthritis of hip jointJPRN-UMIN000027501Yokohama City University90
进行中（未招募）
1 期
En randomiseret kontrolleret undersøgelse af alendronat som forebyggende behandling mod udvikling af glucocorticoid induceret osteoporose hos patienter der behandles for malignt lymfom.Age = 18 years. Patients with new diagnosis or recurrence of lymphoma, which is expected to be treated with one of the listed chemotherapy regimens.Expected lifespan =2 yearsMedDRA version: 19.0Level: LLTClassification code 10025315Term: Lymphoma malignantSystem Organ Class: 100000004864EUCTR2015-005688-18-DKDepartment of Hematology, Aalborg University Hospital60
已完成
不适用
Clinical study on efficacy of alendronate infusion for pediatric osteogenesis imperfecta (including severe form)osteogenesis imperfectaJPRN-UMIN000010615Tohoku University School of Medicine, Department of Pediatrics10
已完成
不适用
The effect of combination therapy with Alendronate and Eldecalcitol for glucocorticoid induced osteoporosis -switch from Alfacalcidol to Eldecalcitolglucocorticoid induced osteoporosisJPRN-UMIN000009588Department of Rheumatic Disease, Shinko Hospital60
进行中（未招募）
1 期
Study of the antiresorptive treatment with alendronate versus no treatment after denosumab and aromatase inhibitors discontinuation in low fracture risk osteopenic postmenopausal women with non metastatic hormonal receptor positive breast cancer.EUCTR2020-005343-23-ITIRCCS ISTITUTO ORTOPEDICO GALEAZZI S.P.A190